Woo Sungmin, Becker Anton S, Leithner Doris, Charbel Charlotte, Mayerhoefer Marius E, Friedman Kent P, Tong Angela, Murina Sofya, Siskin Matthew, Taneja Samir S, Zelefsky Michael J, Wise David R, Vargas Hebert A
Department of Radiology, NYU Langone Health, New York, NY, USA.
Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY, USA.
Eur Radiol. 2025 Mar 20. doi: 10.1007/s00330-025-11514-3.
Prostate-specific membrane antigen (PSMA)-PET/CT has become integral to management of prostate cancer; however, PSMA-avid rib lesions pose a diagnostic challenge. This study investigated clinicopathological and imaging findings that predict metastatic etiology of PSMA-avid rib lesions.
Consecutive patients with prostate cancer that underwent PET/CT with [F]F-DCFPyL in 2021-2023 for newly diagnosed intermediate-/high-risk prostate cancer or recurrent/metastatic disease and had PSMA-avid rib lesions were included. Imaging findings assessed were: lesion number, PSMA expression (maximum standard uptake value (SUV), miPSMA score), CT features (sclerotic, lucent, fracture, no correlate), other sites of metastases, and primary tumor findings. A composite reference standard for rib lesion etiology (metastatic vs non-metastatic) based on histopathology, serial imaging, and clinical assessment was used.
One hundred and seventy-five men (median 71 years, IQR 65-77) with PSMA-avid rib lesions were included; 47/175 (26.9%) had rib metastases. Only 1/47 (2.1%) of these patients had isolated rib metastasis without PSMA-avid metastases in other bones, nodes, or visceral organs; the other 46/47 (97.9%) patients with rib metastases also had other sites of PSMA-avid disease. Patients with rib metastases were older, had higher prostate-specific antigen levels, and higher-grade tumors (p < 0.01). Metastatic rib lesions had higher uptake (SUV, miPSMA), more commonly involved multiple ribs, and were more often sclerotic (p < 0.01); lucency/fractures were only seen in benign lesions.
Several imaging and clinicopathological factors differed between PSMA-avid metastatic and benign lesions. Isolated rib lesions without other sites of metastasis are almost always benign. Careful assessment of CT features can help diagnose benign lesions.
Question While prostate-specific membrane antigen (PSMA)-PET/CT has become integral to the management of prostate cancer, PSMA-avid rib lesions pose a diagnostic challenge. Findings Approximately a quarter of patients who had PSMA-avid rib lesions were metastatic. However, only 2.1% of them had isolated rib metastasis (without PSMA-avid metastases elsewhere). Clinical relevance Isolated PSMA-avid rib lesions are almost always benign when there is no evidence of metastatic disease elsewhere. Scrutinizing CT features can help diagnose benign PSMA-avid lesions with greater certainty.
前列腺特异性膜抗原(PSMA)-PET/CT已成为前列腺癌管理的重要组成部分;然而,PSMA摄取阳性的肋骨病变带来了诊断挑战。本研究调查了预测PSMA摄取阳性肋骨病变转移病因的临床病理和影像学表现。
纳入2021年至2023年因新诊断的中/高危前列腺癌或复发/转移性疾病接受[F]F-DCFPyL PET/CT检查且有PSMA摄取阳性肋骨病变的前列腺癌连续患者。评估的影像学表现包括:病变数量、PSMA表达(最大标准摄取值(SUV)、微PSMA评分)、CT特征(硬化、透亮、骨折、无对应表现)、其他转移部位以及原发肿瘤表现。采用基于组织病理学、系列影像学和临床评估的肋骨病变病因(转移性与非转移性)综合参考标准。
纳入175例有PSMA摄取阳性肋骨病变的男性(中位年龄71岁,四分位间距65 - 77岁);47/175(26.9%)有肋骨转移。这些患者中只有1/47(2.1%)有孤立性肋骨转移,其他骨骼、淋巴结或内脏器官无PSMA摄取阳性转移;其他46/47(97.9%)有肋骨转移的患者也有其他PSMA摄取阳性疾病部位。有肋骨转移的患者年龄更大,前列腺特异性抗原水平更高,肿瘤分级更高(p < 0.01)。转移性肋骨病变摄取更高(SUV、微PSMA),更常累及多根肋骨,且更常为硬化性(p < 0.01);透亮/骨折仅见于良性病变。
PSMA摄取阳性的转移性和良性病变在几个影像学和临床病理因素上存在差异。无其他转移部位的孤立性肋骨病变几乎总是良性的。仔细评估CT特征有助于诊断良性病变。
问题虽然前列腺特异性膜抗原(PSMA)-PET/CT已成为前列腺癌管理的重要组成部分,但PSMA摄取阳性的肋骨病变带来了诊断挑战。发现约四分之一有PSMA摄取阳性肋骨病变的患者发生了转移。然而,其中只有2.1%有孤立性肋骨转移(其他部位无PSMA摄取阳性转移)。临床意义当无其他部位转移证据时,孤立性PSMA摄取阳性肋骨病变几乎总是良性的。仔细检查CT特征有助于更准确地诊断良性PSMA摄取阳性病变。